A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets

Journal of Pharmaceutical and Biomedical Analysis

Volumn 45, Issue 2, 2007, Pages 263-267

  Li, Jia ^a,b   Wang, Yulan ^a   Fenwick, Alan ^a   Clayton, T Andrew ^a   Lau, Yu Y K ^a   Legido Quigley, Cristina ^c   Lindon, John C ^a   Utzinger, Jürg ^b   Holmes, Elaine ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

High performance liquid chromatography; Nuclear magnetic resonance spectroscopy; Praziquantel; Principal component analysis; Quality control; Schistosomiasis

Indexed keywords

EXCIPIENT; METHYL PARABEN; PRAZIQUANTEL;

ARTICLE; DRUG MANUFACTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POWDER; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TABLET; ULTRAVIOLET RADIATION;

ANTHELMINTICS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PRAZIQUANTEL; PRINCIPAL COMPONENT ANALYSIS; QUALITY CONTROL; TABLETS;

EID: 34948834220     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2007.06.017     Document Type: Article

References (24)

1. WHO, WHO Techn. Rep. Ser. No. 912, 2002.
2. Fenwick A., Keiser J., and Utzinger J. Drug Future 31 (2006) 413-425
3. Utzinger J., and Keiser J. Expert Opin. Pharmacol. 5 (2004) 263-285
4. Fenwick A., Savioli L., Engels D., Bergquist N.R., and Todd M.H. Trends Parasitol. 19 (2003) 509-515
5. WHO, WHO Techn. Rep. Ser. No. 849, 1995.
6. Keiser J., and Utzinger J. Expert Opin. Pharmacol. 5 (2004) 1711-1726
7. Chen M.G. Acta Trop. 96 (2005) 168-176
8. Lammie P.J., Fenwick A., and Utzinger J. Trends Parasitol. 22 (2006) 313-321
9. Kusel J., and Hagan P. Parasitol. Today 15 (1999) 352-354
10. Cioli D. Parasitol. Today 14 (1998) 418-422
11. Renganathan E., and Cioli D. Parasitol. Today 14 (1998) 390-391
12. Appleton C.C., and Mbaye A. Trends Parasitol. 17 (2001) 356-357
13. Sulaiman S.M., Traore M., Engels D., Hagan P., and Cioli D. Lancet 358 (2001) 666-667
14. European Pharmacopoeia, 5th ed., Council of Europe, Strasbourg, 2005.
15. Wang Y.L., Tang H.R., Nicholson J.K., Hylands P.J., Sampson J., Whitcombe I., Stewart C.G., Caiger S., Oru I., and Holmes E. Planta Med. 70 (2004) 250-255
16. Bailey N.J.C., Sampson J., Hylands P.J., Nicholson J.K., and Holmes E. Planta Med. 68 (2002) 734-738
17. Bailey N.J.C., Wang Y.L., Sampson J., Davis W., Whitcombe I., Hylands P.J., Croft S.L., and Holmes E. J. Pharm. Biomed. Anal. 35 (2004) 117-126
18. Winter W., Deubner R., and Holzgrabe U. J. Pharm. Biomed. Anal. 38 (2005) 833-839
19. Lommen A., Schilt R., Weseman J., Roos A.H., van Velde J.W., and Nielen M.W.F. J. Pharm. Biomed. Anal. 28 (2002) 87-96
20. Nicholson J.K., Foxall P.J.D., Spraul M., Farrant R.D., and Lindon J.C. Anal. Chem. 67 (1995) 793-811
21. Wold S., Esbensen K., and Geladi P. Chemometr. Intell. Lab. 2 (1987) 37-52
22. Newton P.N., Green M.D., Fernandez F.M., Day N.P.J., and White N.J. Lancet Infect. Dis. 6 (2006) 602-613
23. Carter J.F., Titterton E.L., Murray M., and Sleeman R. Analyst 127 (2002) 830-833
24. Dang H.V., Gray A.I., Watson D., Bates C.D., Scholes P., and Eccleston G.M. J. Pharm. Biomed. Anal. 40 (2006) 1155-1165